Encephalitis Induced by Durvalumab During Treatment of Metastatic Small-Cell Lung Cancer: Illustrative Case and Review of the Literature.
Aged
Antibodies
/ blood
Antibodies, Monoclonal
/ adverse effects
Antineoplastic Agents, Immunological
/ adverse effects
Autoimmune Diseases
/ chemically induced
Female
Humans
Limbic Encephalitis
/ chemically induced
Lung Neoplasms
/ diagnostic imaging
Receptors, GABA-B
/ immunology
Small Cell Lung Carcinoma
/ diagnostic imaging
Journal
Journal of immunotherapy (Hagerstown, Md. : 1997)
ISSN: 1537-4513
Titre abrégé: J Immunother
Pays: United States
ID NLM: 9706083
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
received:
31
12
2020
accepted:
02
02
2021
pubmed:
19
3
2021
medline:
22
3
2022
entrez:
18
3
2021
Statut:
ppublish
Résumé
The immune checkpoint inhibitors have improved the standards of care in cancer treatment and have dramatically improved patient prognoses. These new antibodies turned to be an integral part of the standard of care for metastatic small-cell lung cancer. Platinum-based chemotherapy combined with checkpoint inhibitors, resulted in statistically significant improvement of progression free survival and overall survival. Immune checkpoint inhibitors immune-related adverse events have been observed and reported as a consequence of administering these innovative treatment drugs. Neurological immune-related adverse events are rare complications; however, they can be potentially fatal, particularly encephalitis. This report describes a 66-year-old female who received Durvalumab for metastatic small-cell lung cancer. Following 3 cycles of treatment, she developed encephalitis.
Identifiants
pubmed: 33734140
doi: 10.1097/CJI.0000000000000362
pii: 00002371-202109000-00001
doi:
Substances chimiques
Antibodies
0
Antibodies, Monoclonal
0
Antineoplastic Agents, Immunological
0
Receptors, GABA-B
0
durvalumab
28X28X9OKV
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
243-247Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Immune Checkpoint Inhibitors. National Cancer Institute Web site. 2019. Available at: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors . Accessed December 7, 2020.
Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016;21:821–833.
Scott JA, Augusto V, Davey D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Eng J Med. 2017;377:1919–1929.
Herbst RS. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328–1339.
Paz-Ares L. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–1939.
Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology (Oxford). 2019;58(suppl 7):vii59–vii-67.
Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolmab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22:709–718.
Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1–8.
Burke M, Hardesty M, Downs W. A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer. Gynecol Oncol Rep. 2018;24:51–53.
Shah S, Dunn-Pirio A, Luedje M, et al. Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma. Case Rep Neurol Med. 2018;2018:2548528.
Khan Z, Hammer C, Guardino E, et al. Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach. Genome Med. 2019;11:39.
Winter SF, Vaios EJ, Dietrich J. Central nervous system injury from novel cancer immunotherapies. Curr Opin Neurol. 2020;33:723–735.
Reynolds KL, Guidon AC. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist. 2019;24:435–443.
Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol. 2010;257:509–517.
Oyanguren B, Sánchez V, González FJ, et al. Limbic encephalitis: a clinical-radiological comparison between herpetic and autoimmune etiologies. Eur J Neurol. 2013;20:1566–1570.
Common Terminology Criteria for Adverse Events; Version 5.0, 2009. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf . Accessed January 10, 2021.
Kang K, Zheng K, Zhang Y. Paraneoplastic encephalitis and enteric neuropathy associated with anti-Hu antibody in a patient following immune-checkpoint inhibitor therapy. J Immunother. 2020;43:165–168.
Cellucci T, Van Mater H, Graus F, et al. Clinical approach to the diagnosis of autoimmune encephalitis in pediatric patient. Neurol Neuroimmunol Neuroinflamm. 2020;7:e663.
Nersesjan V, McWilliam O, Krarup LH, et al. Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: systemic review. medRxiv. 2020. Available at: https://doi.org/10.1101/2020.08.31.20185009 .
doi: 10.1101/2020.08.31.20185009
Shin YW, Lee ST, Park KI, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2018;11:1756285617722347.
Lancaster E. The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol. 2016;12:1–3.
Niki M, Nakaya A, Kurata T, et al. Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer. Mol Clin Oncol. 2019;10:267–269.
Cui J, Bu H, He J, et al. The gamma-aminobutyric acid-B receptor (GABAB) encephalitis: clinical manifestations and response to immunotherapy. Int J Neurosci. 2018;128:627–633.